266 related articles for article (PubMed ID: 31296355)
21. [Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey].
Göl MF; Kara F; Boz M; Mutlu A; Karakullukçu S; Boz C
Ideggyogy Sz; 2022 Sep; 75(9-10):351-359. PubMed ID: 36218113
[TBL] [Abstract][Full Text] [Related]
22. Myasthenia gravis with antibodies to MuSK: an update.
Evoli A; Alboini PE; Damato V; Iorio R; Provenzano C; Bartoccioni E; Marino M
Ann N Y Acad Sci; 2018 Jan; 1412(1):82-89. PubMed ID: 29266255
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
24. Long-lasting treatment effect of rituximab in MuSK myasthenia.
Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
[TBL] [Abstract][Full Text] [Related]
25. Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review.
Bennani HN; Lagrange E; Noble J; Malvezzi P; Motte L; Chevallier E; Rostaing L; Jouve T
J Clin Apher; 2021 Jun; 36(3):348-363. PubMed ID: 33349954
[TBL] [Abstract][Full Text] [Related]
26. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
[TBL] [Abstract][Full Text] [Related]
27. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
Pasnoor M; He J; Herbelin L; Burns TM; Nations S; Bril V; Wang AK; Elsheikh BH; Kissel JT; Saperstein D; Shaibani JA; Jackson C; Swenson A; Howard JF; Goyal N; David W; Wicklund M; Pulley M; Becker M; Mozaffar T; Benatar M; Pazcuzzi R; Simpson E; Rosenfeld J; Dimachkie MM; Statland JM; Barohn RJ;
Neurology; 2016 Jul; 87(1):57-64. PubMed ID: 27306628
[TBL] [Abstract][Full Text] [Related]
28. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis.
Robeson KR; Kumar A; Keung B; DiCapua DB; Grodinsky E; Patwa HS; Stathopoulos PA; Goldstein JM; O'Connor KC; Nowak RJ
JAMA Neurol; 2017 Jan; 74(1):60-66. PubMed ID: 27893014
[TBL] [Abstract][Full Text] [Related]
29. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
[TBL] [Abstract][Full Text] [Related]
30. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
[TBL] [Abstract][Full Text] [Related]
31. Anti-MuSK myasthenia gravis with prolonged remission.
Bouwyn JP; Magnier P; Bédat-Millet AL; Ahtoy P; Maltête D; Lefaucheur R
Neuromuscul Disord; 2016 Jul; 26(7):453-4. PubMed ID: 27161384
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
Koul R; Al Futaisi A; Abdwani R
Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
[TBL] [Abstract][Full Text] [Related]
34. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
35. [Rituximab for the treatment of generalised myasthenia gravis: experience in clinical practice].
Martínez-Monte E; Gascón-Giménez F; Domínguez-Morán JA; Láinez-Andres JM
Rev Neurol; 2021 Nov; 73(12):416-420. PubMed ID: 34877644
[TBL] [Abstract][Full Text] [Related]
36. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody.
Punga AR; Flink R; Askmark H; Stålberg EV
Muscle Nerve; 2006 Jul; 34(1):111-5. PubMed ID: 16453324
[TBL] [Abstract][Full Text] [Related]
37. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
Keung B; Robeson KR; DiCapua DB; Rosen JB; O'Connor KC; Goldstein JM; Nowak RJ
J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1407-9. PubMed ID: 23761915
[No Abstract] [Full Text] [Related]
38. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
Iorio R; Damato V; Alboini PE; Evoli A
J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
[TBL] [Abstract][Full Text] [Related]
39. [Effects of acetylcholinesterase inhibitors on patients with MuSK antibody positive myasthenia gravis].
Konishi T; Kousaka M; Yamakawa K; Matsui M; Ohta K
Rinsho Shinkeigaku; 2009 Oct; 49(10):660-3. PubMed ID: 19999149
[TBL] [Abstract][Full Text] [Related]
40. Use and monitoring of low dose rituximab in myasthenia gravis.
Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
